Das metastasierte Urothelkarzinom – leitlinienorientierte Therapie und neue Optionen

Translated title of the contribution: Metastatic urothelial carcinoma—guideline-based therapy and new options

Günter Niegisch, Gunhild von Amsberg, Marc Rehlinghaus, Camilla M. Grunewald, Margitta Retz

Research output: Contribution to journalArticlepeer-review

Abstract

Due to the approval of immuno-oncological therapies with immune checkpoint inhibitors, the treatment of metastatic urothelial carcinoma has become more complex in all lines of therapy. Thus, in first-line treatment, immunotherapy alone or immune maintenance therapy following platinum-based chemotherapy can be applied in addition to treatment with platinum-based combination therapies alone. In addition to the approval status and guideline recommendation, patient-specific factors such as comorbidities as well as patient preference must always be considered when choosing a therapy. In the following, we summarize the current data on treatment options in the first-line therapy of metastatic urothelial carcinoma and illustrate their practical application using a patient example.

Translated title of the contributionMetastatic urothelial carcinoma—guideline-based therapy and new options
Original languageGerman
Pages (from-to)132-138
Number of pages7
JournalJournal fur Urologie und Urogynakologie
Volume29
Issue number4
DOIs
StatePublished - Dec 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Metastatic urothelial carcinoma—guideline-based therapy and new options'. Together they form a unique fingerprint.

Cite this